AbbVie Inc.
ABBVNext catalyst
Lutikizumab
Hidradenitis Suppurativa
Get an email about ABBV's next catalysts
Track AbbVie (ABBV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 35 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
37 upcoming, 5 past
ABBV-400 Phase 2 Est. Readout
Estimated primary completion for ABBV-400 trial (NCT06107413) in Unresectable Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.
SourceLutikizumab Phase 3 Est. Readout (Intrepid)
Estimated primary completion for Lutikizumab trial (NCT06468228) in Hidradenitis Suppurativa. Topline data typically follows completion by weeks to months.
SourceVenetoclax Phase 2 Est. Readout
Estimated primary completion for Venetoclax trial (NCT06284486) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceData Readout
Alkermes' orexin drug demonstrated proof-of-concept in ADHD with results anticipated in 2027, while AbbVie advanced AI drug discovery efforts and the FDA expanded use of Eli Lilly's breast cancer medication.
New data for Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma
SourceLiposomal daunorubicin and cytarabine Phase 2 Est. Readout
Estimated primary completion for Liposomal daunorubicin and cytarabine trial (NCT04801797) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceLivmoniplimab Phase 3 Est. Readout (LIVIGNO-2)
Estimated primary completion for Livmoniplimab trial (NCT06109272) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceTelisotuzumab Vedotin Phase 2 Est. Readout
Estimated primary completion for Telisotuzumab Vedotin trial (NCT07323641) in Lung Non-Small Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceLutikizumab Phase 2 Est. Readout
Estimated primary completion for Lutikizumab trial (NCT06972446) in Rheumatoid Arthritis. Topline data typically follows completion by weeks to months.
SourceHow ABBV's past catalysts played out
Market Overview
Stock performance and key metrics
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
WebsiteEstradiol/Norethindrone Acetate
Endometriosis
Risankizumab On-Body Injector (OBI)
Crohn's Disease
Bimatoprost (SR)
Open-Angle Glaucoma
etanercept
Moderate to Severe Plaque Psoriasis
Etentamig
Multiple Myeloma
Acalabrutinib
Chronic Lymphocytic Leukemia
Elagolix
Polycystic Ovary Syndrome
ABT-SLV187
Advanced Parkinson's Disease
ABT-450/r/ABT-267, ABT-333
Chronic Hepatitis C Infection
Paricalcitol
Chronic Kidney Disease Stage 3 and 4
ABT-493/ABT-530
Hepatitis C Virus Infection
sofosbuvir (SOF)
Chronic Hepatitis C Virus
RBV
HCV
Risankizumab SC
Crohn's Disease
Navitoclax
Myelofibrosis (MF)
Tocilizumab
Juvenile Idiopathic Arthritis
Fumaderm
Psoriasis
Fluvoxamine maleate
Obsessive Compulsive Disorder
maxacalcitol
Secondary Hyperparathyroidism
Optimized Medical Treatment
Advanced Parkinson's Disease
Surabgene Lomparvovec (ABBV-RGX-314)
Neovascular Age-related Macular Degeneration
Ranibizumab (LUCENTIS®)
AMD
ABT-712
Chronic Low Back Pain
Ubrogepant
Migraine
Dasabuvir
Chronic Hepatitis C Infection
Palivizumab
Respiratory Syncytial Virus (RSV)
secukinumab
Psoriasis
Telaprevir
Chronic Hepatitis C Infection
Upadacitinib (ABT-494)
Ulcerative Colitis (UC)
AGN-190584
Presbyopia
Topical corticosteroids (TCS)
Atopic Dermatitis
OBV/PTV/r
Chronic Hepatitis C Virus
Botulinum Toxin Type A
Masseter Muscle Prominence
Linaclotide
Functional Constipation (FC)
Ibrutinib
Mantle Cell Lymphoma (MCL)
ABT-267
Chronic Hepatitis C
2 DAA
HCV
Glecaprevir/Pibrentasvir Adult Formulation
Hepatitis C Virus (HCV)
Upadacitinib
Ulcerative Colitis (UC)
ombitasvir/paritaprevir/ritonavir and dasabuvir
Hepatitis C Virus (HCV)
Veliparib
Metastatic Breast Cancer
adalimumab
Pyoderma Gangrenosum
Risankizumab
Crohn's Disease (CD)
Rovalpituzumab tesirine
Small Cell Lung Cancer
ombitasvir/paritaprevir/ritonavir
Hepatitis C Infection
Cariprazine
Depression
ABBV-951
Parkinson's Disease (PD)
BOTOX
Masseter Muscle Prominence
Corticosteroid (CS)
Giant Cell Arteritis (GCA)
Venetoclax
Acute Myeloid Leukemia (AML)
Pegylated Interferon a-2a (PegINF)
Chronic Hepatitis C Infection
ABT-493, ABT-530
Chronic Hepatitis C
Combined Oral Contraceptive
Endometriosis
ABT-530
Chronic Hepatitis C
LUMIGAN
Open-Angle Glaucoma
Optimized antiparkinsonian treatment
Parkinson's Disease (PD)
Lutikizumab
Hidradenitis Suppurativa
Telisotuzumab vedotin
Non-small Cell Lung Cancer
Bimatoprost SR
Open-Angle Glaucoma
ABT-333
Chronic Hepatitis C Infection
Glecaprevir/Pibrentasvir
Hepatitis C Virus (HCV)
Vedolizumab
Ulcerative Colitis
ABT-493
Chronic Hepatitis C
OnabotulinumtoxinA
Forehead Lines
Dalbavancin
Methicillin-Resistant Staphylococcus Aureus
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Abatacept
Rheumatoid Arthritis (RA)
Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer
AGN-151586
Glabellar Lines
Atogepant
Chronic Migraine
Best Available Therapy (BAT)
Myelofibrosis (MF)
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)
Irritable Bowel Syndrome With Constipation
ABBV-444
Dry Eye Disease
Trifluridine/Tipiracil
Metastatic Colorectal Cancer
Armour Thyroid
Hypothyroidism
ABT-874
Plaque Psoriasis
Antidepressant Therapy (ADT)
Major Depressive Disorder
Estradiol/norethindrone acetate (E2/NETA)
Heavy Menstrual Bleeding
Leuprolide Acetate (LA)
Central Precocious Puberty (CPP)
risankizumab IV
Crohn Disease
Open-label Adalimumab
Axial Spondyloarthritis
Sofosbuvir
Chronic Hepatitis C
ombitasvir/paritaprevir/ritonavir, dasabuvir
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Topiramate
Migraine
Livmoniplimab
Hepatocellular Carcinoma
Budigalimab
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Cariprazine Flexible Dose
Schizophrenia
ABT-450/r/ABT-267
Hepatitis C Virus Infection
Elotuzumab
Multiple Myeloma
Glecaprevir/Pibrentasvir (GLE/PIB)
Hepatitis C Virus (HCV)
Surabgene Lomparvovec
Diabetic Retinopathy
Tavapadon
Parkinson Disease
ABT-493 coformulated with ABT-530
Hepatitis C Virus Infection
Levodopa-carbidopa intestinal gel
Advanced Parkinson's Disease
Ribavirin (RBV)
Chronic Hepatitis C Virus (HCV) Infection
Levodopa-carbidopa Immediate Release (LC-IR) Tablets
Advanced Parkinson's Disease
Ranibizumab Control
Neovascular Age-related Macular Degeneration
Ombitasvir mini tablet
Chronic Hepatitis C Infection
Paritaprevir mini tablet
Chronic Hepatitis C Infection
Ritonavir mini tablet
Chronic Hepatitis C Infection
Dasabuvir mini tablet
Chronic Hepatitis C Infection
Ribavirin solution
Chronic Hepatitis C Infection
Levodopa carbidopa intestinal gel (LCIG)
Advanced Parkinson's Disease
Glecaprevir + Pibrentasvir Pediatric Formulation
Hepatitis C Virus (HCV)
Folinic acid/Leucovorina
Metastatic Pancreatic Ductal Adenocarcinoma
NOA LIFT
Nasolabial Folds
Dexamethasone (IV)
Lymphoma
Dexamethasone (Oral)
Lymphoma
Upadacitinib Oral Product
Colitis, Ulcerative
Paritaprevir/ritonavir/ombitasvir
Hepatitis C, Acute
Levothyroxine
Hypothyroidism
Nab- Paclitaxel
Non-Small Cell Lung Cancer
Pivekimab Sunirine
Acute Myeloid Leukemia
ABBV-1480
Non-Small Cell Lung Cancer
Elotuzumab (BMS-901608; HuLuc63)
Multiple Myeloma
AGN-193408 SR
Open-angle Glaucoma
MEDI0618
Migraine
ABT-719
Acute Kidney Injury
ABBV-706
Small Cell Lung Cancer
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Endometriosis
ABT-199
Acute Myelogenous Leukemia
ABBV-8E12
Alzheimer's Disease
Erwinia asparaginase
Refractory Acute Lymphoblastic Leukemia
Creon36™
Chronic Pancreatitis
BIIB019 (Daclizumab High Yield Process)
Relapsing-Remitting Multiple Sclerosis
Intrathecal Triples
Refractory Acute Lymphoblastic Leukemia
ABT-072
Hepatitis C Virus Infection
APG777
Atopic Dermatitis
Brimonidine tartrate ophthalmic solution eye drops
Recurrent Ovarian Cancer
Thioguanine
T-cell Acute Lymphoblastic Leukemia
ABBV-8736
Crohn's Disease
Adalimumab-800CW
IBD
Pancreatic Enzyme
Short Bowel Syndrome
Prednisolone acetate ophthalmic suspension eye drops
Recurrent Ovarian Cancer
Calaspargase pegol
T-cell Acute Lymphoblastic Leukemia
Recombinant Granulocyte Colony-Stimulating Factor
Acute Biphenotypic Leukemia
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
T-cell Acute Lymphoblastic Leukemia
Trosunilimab
Crohn's Disease
Pegylated interferon (pegIFN)
Chronic Hepatitis C
Ritonavir
Chronic Hepatitis C Infection
ABT-450
Hepatitis C Virus
Emraclidine
Schizophrenia
ABBV-382
Crohn's Disease
ABT-894
Diabetic Neuropathic Pain
ABT-981
Erosive Hand Osteoarthritis
Omaveloxolone
MItochondrial Myopathies
ABT-494
Crohn's Disease
Ranibizumab
Neovascular Age-Related Macular Degeneration (nAMD)
ABT-263
Chronic Lymphoid Leukemia
dexamethasone injection
Hematologic Cancer
ABT-888
Melanoma
ABBV-400
Unresectable Metastatic Colorectal Cancer
rituximab/IDEC-C2B8
Non-Hodgkin Lymphoma (NHL)
ABBV-142
Idiopathic Pulmonary Fibrosis
Onureg + Venetoclax
Untreated Myelodysplastic Syndrome
ABBV-2001
Multiple Myeloma
Ravagalimab
Rheumatoid Arthritis
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Relapsed or Refractory Acute Myeloid Leukemia (AML)
ABT-450/r
Chronic Hepatitis C
ABBV-701
Crohn's Disease
ABT-089
Attention Deficit Hyperactivity Disorder
venetoclax + azacitidine +/- donor lymphocyte infusion
MDS
hydrocodone/acetaminophen extended release
Chronic Low Back Pain
atomoxetine
Attention-Deficit/Hyperactivity Disorder
Elsubrutinib
Systemic Lupus Erythematosus (SLE)
ABT199
Waldenstrom Macroglobulinemia
onabotulinum toxin A
Neuropathic Pain
elezanumab
Multiple Sclerosis (MS)
ABT-869
Advanced Hepatocellular Carcinoma
ABBV-6628
Geographic Atrophy
JAB-3068
Advanced Solid Tumor
ABT-450/ritonavir (r)
Chronic Hepatitis C
Depatuxizumab mafodotin
Glioblastoma
Multiple-dose ATM-AVI, Cohorts 1-4
Gram-negative Bacterial Infection
CVL-865
Seizures
GM-2505
Major Depressive Disorder
PD1 inhibitor
Advanced Solid Tumor
AGN-151607
Post-Operative Atrial Fibrillation
AGN-242428
Dry Eye Disease
ABBV-453
Multiple Myeloma
ABT-122
Rheumatoid Arthritis
TrenibotulinumtoxinE and OnabotulinumtoxinA
Upper Facial Lines
Venetoclax plus Azacitidine
Acute Myeloid Leukemia
JAB-3312
Solid Tumor
Leuprorelin Acetate Depot
Endometriosis
azacitadine
Non-Hodgkin Lymphoma (NHL)
ABBV-932
Generalized Anxiety Disorder (GAD)
ABT-414
Malignant Glioma
Daunorubicin Hydrochloride
Acute Myeloid Leukemia
ABBV-552
Alzheimer's Disease (AD)
Ombitasvir/ABT-450/Ritonavir
Chronic Hepatitis C
ABT-126
Schizophrenia
ABBV-668
Ulcerative Colitis
Topical Steroid
Diabetic Retinopathy (DR)
Venetoclax Oral Tablet
Relapsed Adult AML
Idarubicin Hydrochloride
Acute Myeloid Leukemia
Mitoxantrone Hydrochloride
Acute Myeloid Leukemia
Surzetoclax
Multiple Myeloma
Icalcaprant
Major Depressive Disorder
Tagraxofusp
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
CVL-231
Schizophrenia
ABBV-3067
Cystic Fibrosis
Mirvetuximab Soravtansine-gynx
Ovary Cancer
Lubricating Eye Drops
Recurrent Ovarian Cancer
SYFOVRE
Geographic Atrophy
Alternately treated with VA/low CHA regimen
Intensive Chemotherapy Unfit
AGN-231868
Dry Eye Disease
venetoclax and ibrutinib (I+VEN)
Intermediate Risk Chronic Lymphocytic Leukemia
Atrasentan high dose group
Chronic Kidney Disease
ABT-639
Diabetic Neuropathic Pain
ABT-199 (Main Cohort)
Chronic Lymphocytic Leukemia
ABT-288 High Dose
Cognitive Deficits in Schizophrenia
IMGN632
Acute Myeloid Leukemia
ABT-199 (Safety Expansion Cohort)
Chronic Lymphocytic Leukemia
CVL-871
Apathy in Dementia
AGN-151607-DP
Ventral Hernia
ABT-751
Lung Cancer
Liposomal daunorubicin and cytarabine
Acute Myeloid Leukemia
ABBV-916
Alzheimer's Disease (AD)
TNB-383B
Multiple Myeloma
Revumenib
Acute Myeloid Leukemia
Modified FOLFIRI
Untreated Metastatic Colorectal Cancer
Darigabat
Panic Disorder
IMGN151
Gynecologic Cancers
AGN-151597
Advanced Retinitis Pigmentosa
Oral Levodopa/Carbidopa
Advanced Parkinson's Disease
ABBV-3373
Rheumatoid Arthritis (RA)
Lenvatinib
Hepatocellular Carcinoma
Eluxadoline
Irritable Bowel Syndrome
Panitumumab
Metastatic Colorectal Cancer
ABBV-383 (Etentamig)
Immunoglobulin Light Chain (AL) Amyloidosis
Pneumococcal 13-valent conjugate vaccine (PCV-13)
Rheumatoid Arthritis
Atrasentan
Nephropathy
Fluorouracil infusion
Untreated Metastatic Colorectal Cancer
ABBV-295
Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Estradiol/Norethindrone Acetate | Phase 3 | Endometriosis | - | - |
Risankizumab On-Body Injector (OBI) | Phase 3 | Crohn's Disease | - | - |
Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma | - | - |
etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis | - | - |
Etentamig | Phase 3 | Multiple Myeloma | - | - |
Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Elagolix | Phase 3 | Polycystic Ovary Syndrome | - | - |
ABT-SLV187 | Phase 3 | Advanced Parkinson's Disease | - | - |
ABT-450/r/ABT-267, ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Paricalcitol | Phase 3 | Chronic Kidney Disease Stage 3 and 4 | - | - |
ABT-493/ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
sofosbuvir (SOF) | Phase 3 | Chronic Hepatitis C Virus | - | - |
RBV | Phase 3 | HCV | - | - |
Risankizumab SC | Phase 3 | Crohn's Disease | - | - |
Navitoclax | Phase 3 | Myelofibrosis (MF) | - | - |
Tocilizumab | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
Fumaderm | Phase 3 | Psoriasis | - | - |
Fluvoxamine maleate | Phase 3 | Obsessive Compulsive Disorder | - | - |
maxacalcitol | Phase 3 | Secondary Hyperparathyroidism | - | - |
Optimized Medical Treatment | Phase 3 | Advanced Parkinson's Disease | - | - |
Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Ranibizumab (LUCENTIS®) | Phase 3 | AMD | - | - |
ABT-712 | Phase 3 | Chronic Low Back Pain | - | - |
Ubrogepant | Phase 3 | Migraine | - | - |
Dasabuvir | Phase 3 | Chronic Hepatitis C Infection | - | - |
Palivizumab | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
secukinumab | Phase 3 | Psoriasis | - | - |
Telaprevir | Phase 3 | Chronic Hepatitis C Infection | - | - |
Upadacitinib (ABT-494) | Phase 3 | Ulcerative Colitis (UC) | - | - |
AGN-190584 | Phase 3 | Presbyopia | - | - |
Topical corticosteroids (TCS) | Phase 3 | Atopic Dermatitis | - | - |
OBV/PTV/r | Phase 3 | Chronic Hepatitis C Virus | - | - |
Botulinum Toxin Type A | Phase 3 | Masseter Muscle Prominence | - | - |
Linaclotide | Phase 3 | Functional Constipation (FC) | - | - |
Ibrutinib | Phase 3 | Mantle Cell Lymphoma (MCL) | - | - |
ABT-267 | Phase 3 | Chronic Hepatitis C | - | - |
2 DAA | Phase 3 | HCV | - | - |
Glecaprevir/Pibrentasvir Adult Formulation | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Upadacitinib | Phase 3 | Ulcerative Colitis (UC) | - | - |
ombitasvir/paritaprevir/ritonavir and dasabuvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Veliparib | Phase 3 | Metastatic Breast Cancer | - | - |
adalimumab | Phase 3 | Pyoderma Gangrenosum | - | - |
Risankizumab | Phase 3 | Crohn's Disease (CD) | - | - |
Rovalpituzumab tesirine | Phase 3 | Small Cell Lung Cancer | - | - |
ombitasvir/paritaprevir/ritonavir | Phase 3 | Hepatitis C Infection | - | - |
Cariprazine | Phase 3 | Depression | - | - |
ABBV-951 | Phase 3 | Parkinson's Disease (PD) | - | - |
BOTOX | Phase 3 | Masseter Muscle Prominence | - | - |
Corticosteroid (CS) | Phase 3 | Giant Cell Arteritis (GCA) | - | - |
Venetoclax | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Pegylated Interferon a-2a (PegINF) | Phase 3 | Chronic Hepatitis C Infection | - | - |
ABT-493, ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
Combined Oral Contraceptive | Phase 3 | Endometriosis | - | - |
ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
LUMIGAN | Phase 3 | Open-Angle Glaucoma | - | - |
Optimized antiparkinsonian treatment | Phase 3 | Parkinson's Disease (PD) | - | - |
Lutikizumab | Phase 3 | Hidradenitis Suppurativa | - | - |
Telisotuzumab vedotin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Bimatoprost SR | Phase 3 | Open-Angle Glaucoma | - | - |
ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Glecaprevir/Pibrentasvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
ABT-493 | Phase 3 | Chronic Hepatitis C | - | - |
OnabotulinumtoxinA | Phase 3 | Forehead Lines | - | - |
Dalbavancin | Phase 3 | Methicillin-Resistant Staphylococcus Aureus | - | - |
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Telisotuzumab Adizutecan | Phase 3 | Non-Small Cell Lung Cancer | - | - |
AGN-151586 | Phase 3 | Glabellar Lines | - | - |
Atogepant | Phase 3 | Chronic Migraine | - | - |
Best Available Therapy (BAT) | Phase 3 | Myelofibrosis (MF) | - | - |
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Phase 3 | Irritable Bowel Syndrome With Constipation | - | - |
ABBV-444 | Phase 3 | Dry Eye Disease | - | - |
Trifluridine/Tipiracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
Armour Thyroid | Phase 3 | Hypothyroidism | - | - |
ABT-874 | Phase 3 | Plaque Psoriasis | - | - |
Antidepressant Therapy (ADT) | Phase 3 | Major Depressive Disorder | - | - |
Estradiol/norethindrone acetate (E2/NETA) | Phase 3 | Heavy Menstrual Bleeding | - | - |
Leuprolide Acetate (LA) | Phase 3 | Central Precocious Puberty (CPP) | - | - |
risankizumab IV | Phase 3 | Crohn Disease | - | - |
Open-label Adalimumab | Phase 3 | Axial Spondyloarthritis | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
ombitasvir/paritaprevir/ritonavir, dasabuvir | Phase 3 | Chronic Hepatitis C Virus (HCV Infection Genotype 1) | - | - |
Topiramate | Phase 3 | Migraine | - | - |
Livmoniplimab | Phase 3 | Hepatocellular Carcinoma | - | - |
Budigalimab | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | - | - |
Cariprazine Flexible Dose | Phase 3 | Schizophrenia | - | - |
ABT-450/r/ABT-267 | Phase 3 | Hepatitis C Virus Infection | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Glecaprevir/Pibrentasvir (GLE/PIB) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Surabgene Lomparvovec | Phase 3 | Diabetic Retinopathy | - | - |
Tavapadon | Phase 3 | Parkinson Disease | - | - |
ABT-493 coformulated with ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
Levodopa-carbidopa intestinal gel | Phase 3 | Advanced Parkinson's Disease | - | - |
Ribavirin (RBV) | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection | - | - |
Levodopa-carbidopa Immediate Release (LC-IR) Tablets | Phase 3 | Advanced Parkinson's Disease | - | - |
Ranibizumab Control | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Ombitasvir mini tablet | Phase 3 | Chronic Hepatitis C Infection | - | - |
Paritaprevir mini tablet | Phase 3 | Chronic Hepatitis C Infection | - | - |
Ritonavir mini tablet | Phase 3 | Chronic Hepatitis C Infection | - | - |
Dasabuvir mini tablet | Phase 3 | Chronic Hepatitis C Infection | - | - |
Ribavirin solution | Phase 3 | Chronic Hepatitis C Infection | - | - |
Levodopa carbidopa intestinal gel (LCIG) | Phase 3 | Advanced Parkinson's Disease | - | - |
Glecaprevir + Pibrentasvir Pediatric Formulation | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Folinic acid/Leucovorina | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
NOA LIFT | Phase 3 | Nasolabial Folds | - | - |
Dexamethasone (IV) | Phase 3 | Lymphoma | - | - |
Dexamethasone (Oral) | Phase 3 | Lymphoma | - | - |
Upadacitinib Oral Product | Phase 3 | Colitis, Ulcerative | - | - |
Paritaprevir/ritonavir/ombitasvir | Phase 3 | Hepatitis C, Acute | - | - |
Levothyroxine | Phase 3 | Hypothyroidism | - | - |
Nab- Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Pivekimab Sunirine | Phase 3 | Acute Myeloid Leukemia | - | - |
ABBV-1480 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 3 | Multiple Myeloma | - | - |
AGN-193408 SR | Phase 2 | Open-angle Glaucoma | - | - |
MEDI0618 | Phase 2 | Migraine | - | - |
ABT-719 | Phase 2 | Acute Kidney Injury | - | - |
ABBV-706 | Phase 2 | Small Cell Lung Cancer | - | - |
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) | Phase 2 | Endometriosis | - | - |
ABT-199 | Phase 2 | Acute Myelogenous Leukemia | - | - |
ABBV-8E12 | Phase 2 | Alzheimer's Disease | - | - |
Erwinia asparaginase | Phase 2 | Refractory Acute Lymphoblastic Leukemia | - | - |
Creon36™ | Phase 2 | Chronic Pancreatitis | - | - |
BIIB019 (Daclizumab High Yield Process) | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
Intrathecal Triples | Phase 2 | Refractory Acute Lymphoblastic Leukemia | - | - |
ABT-072 | Phase 2 | Hepatitis C Virus Infection | - | - |
APG777 | Phase 2 | Atopic Dermatitis | - | - |
Brimonidine tartrate ophthalmic solution eye drops | Phase 2 | Recurrent Ovarian Cancer | - | - |
Thioguanine | Phase 2 | T-cell Acute Lymphoblastic Leukemia | - | - |
ABBV-8736 | Phase 2 | Crohn's Disease | - | - |
Adalimumab-800CW | Phase 2 | IBD | - | - |
Pancreatic Enzyme | Phase 2 | Short Bowel Syndrome | - | - |
Prednisolone acetate ophthalmic suspension eye drops | Phase 2 | Recurrent Ovarian Cancer | - | - |
Calaspargase pegol | Phase 2 | T-cell Acute Lymphoblastic Leukemia | - | - |
Recombinant Granulocyte Colony-Stimulating Factor | Phase 2 | Acute Biphenotypic Leukemia | - | - |
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) | Phase 2 | T-cell Acute Lymphoblastic Leukemia | - | - |
Trosunilimab | Phase 2 | Crohn's Disease | - | - |
Pegylated interferon (pegIFN) | Phase 2 | Chronic Hepatitis C | - | - |
Ritonavir | Phase 2 | Chronic Hepatitis C Infection | - | - |
ABT-450 | Phase 2 | Hepatitis C Virus | - | - |
Emraclidine | Phase 2 | Schizophrenia | - | - |
ABBV-382 | Phase 2 | Crohn's Disease | - | - |
ABT-894 | Phase 2 | Diabetic Neuropathic Pain | - | - |
ABT-981 | Phase 2 | Erosive Hand Osteoarthritis | - | - |
Omaveloxolone | Phase 2 | MItochondrial Myopathies | - | - |
ABT-494 | Phase 2 | Crohn's Disease | - | - |
Ranibizumab | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
ABT-263 | Phase 2 | Chronic Lymphoid Leukemia | - | - |
dexamethasone injection | Phase 2 | Hematologic Cancer | - | - |
ABT-888 | Phase 2 | Melanoma | - | - |
ABBV-400 | Phase 2 | Unresectable Metastatic Colorectal Cancer | - | - |
rituximab/IDEC-C2B8 | Phase 2 | Non-Hodgkin Lymphoma (NHL) | - | - |
ABBV-142 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Onureg + Venetoclax | Phase 2 | Untreated Myelodysplastic Syndrome | - | - |
ABBV-2001 | Phase 2 | Multiple Myeloma | - | - |
Ravagalimab | Phase 2 | Rheumatoid Arthritis | - | - |
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen | Phase 2 | Relapsed or Refractory Acute Myeloid Leukemia (AML) | - | - |
ABT-450/r | Phase 2 | Chronic Hepatitis C | - | - |
ABBV-701 | Phase 2 | Crohn's Disease | - | - |
ABT-089 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
venetoclax + azacitidine +/- donor lymphocyte infusion | Phase 2 | MDS | - | - |
hydrocodone/acetaminophen extended release | Phase 2 | Chronic Low Back Pain | - | - |
atomoxetine | Phase 2 | Attention-Deficit/Hyperactivity Disorder | - | - |
Elsubrutinib | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
ABT199 | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
onabotulinum toxin A | Phase 2 | Neuropathic Pain | - | - |
elezanumab | Phase 2 | Multiple Sclerosis (MS) | - | - |
ABT-869 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
ABBV-6628 | Phase 2 | Geographic Atrophy | - | - |
JAB-3068 | Phase 2 | Advanced Solid Tumor | - | - |
ABT-450/ritonavir (r) | Phase 2 | Chronic Hepatitis C | - | - |
Depatuxizumab mafodotin | Phase 2 | Glioblastoma | - | - |
Multiple-dose ATM-AVI, Cohorts 1-4 | Phase 2 | Gram-negative Bacterial Infection | - | - |
CVL-865 | Phase 2 | Seizures | - | - |
GM-2505 | Phase 2 | Major Depressive Disorder | - | - |
PD1 inhibitor | Phase 2 | Advanced Solid Tumor | - | - |
AGN-151607 | Phase 2 | Post-Operative Atrial Fibrillation | - | - |
AGN-242428 | Phase 2 | Dry Eye Disease | - | - |
ABBV-453 | Phase 2 | Multiple Myeloma | - | - |
ABT-122 | Phase 2 | Rheumatoid Arthritis | - | - |
TrenibotulinumtoxinE and OnabotulinumtoxinA | Phase 2 | Upper Facial Lines | - | - |
Venetoclax plus Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
JAB-3312 | Phase 2 | Solid Tumor | - | - |
Leuprorelin Acetate Depot | Phase 2 | Endometriosis | - | - |
azacitadine | Phase 2 | Non-Hodgkin Lymphoma (NHL) | - | - |
ABBV-932 | Phase 2 | Generalized Anxiety Disorder (GAD) | - | - |
ABT-414 | Phase 2 | Malignant Glioma | - | - |
Daunorubicin Hydrochloride | Phase 2 | Acute Myeloid Leukemia | - | - |
ABBV-552 | Phase 2 | Alzheimer's Disease (AD) | - | - |
Ombitasvir/ABT-450/Ritonavir | Phase 2 | Chronic Hepatitis C | - | - |
ABT-126 | Phase 2 | Schizophrenia | - | - |
ABBV-668 | Phase 2 | Ulcerative Colitis | - | - |
Topical Steroid | Phase 2 | Diabetic Retinopathy (DR) | - | - |
Venetoclax Oral Tablet | Phase 2 | Relapsed Adult AML | - | - |
Idarubicin Hydrochloride | Phase 2 | Acute Myeloid Leukemia | - | - |
Mitoxantrone Hydrochloride | Phase 2 | Acute Myeloid Leukemia | - | - |
Surzetoclax | Phase 2 | Multiple Myeloma | - | - |
Icalcaprant | Phase 2 | Major Depressive Disorder | - | - |
Tagraxofusp | Phase 2 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | - | - |
CVL-231 | Phase 2 | Schizophrenia | - | - |
ABBV-3067 | Phase 2 | Cystic Fibrosis | - | - |
Mirvetuximab Soravtansine-gynx | Phase 2 | Ovary Cancer | - | - |
Lubricating Eye Drops | Phase 2 | Recurrent Ovarian Cancer | - | - |
SYFOVRE | Phase 2 | Geographic Atrophy | - | - |
Alternately treated with VA/low CHA regimen | Phase 2 | Intensive Chemotherapy Unfit | - | - |
AGN-231868 | Phase 2 | Dry Eye Disease | - | - |
venetoclax and ibrutinib (I+VEN) | Phase 2 | Intermediate Risk Chronic Lymphocytic Leukemia | - | - |
Atrasentan high dose group | Phase 2 | Chronic Kidney Disease | - | - |
ABT-639 | Phase 2 | Diabetic Neuropathic Pain | - | - |
ABT-199 (Main Cohort) | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
ABT-288 High Dose | Phase 2 | Cognitive Deficits in Schizophrenia | - | - |
IMGN632 | Phase 2 | Acute Myeloid Leukemia | - | - |
ABT-199 (Safety Expansion Cohort) | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
CVL-871 | Phase 2 | Apathy in Dementia | - | - |
AGN-151607-DP | Phase 2 | Ventral Hernia | - | - |
ABT-751 | Phase 2 | Lung Cancer | - | - |
Liposomal daunorubicin and cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
ABBV-916 | Phase 2 | Alzheimer's Disease (AD) | - | - |
TNB-383B | Phase 2 | Multiple Myeloma | - | - |
Revumenib | Phase 2 | Acute Myeloid Leukemia | - | - |
Modified FOLFIRI | Phase 2 | Untreated Metastatic Colorectal Cancer | - | - |
Darigabat | Phase 2 | Panic Disorder | - | - |
IMGN151 | Phase 2 | Gynecologic Cancers | - | - |
AGN-151597 | Phase 2 | Advanced Retinitis Pigmentosa | - | - |
Oral Levodopa/Carbidopa | Phase 2 | Advanced Parkinson's Disease | - | - |
ABBV-3373 | Phase 2 | Rheumatoid Arthritis (RA) | - | - |
Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
Eluxadoline | Phase 2 | Irritable Bowel Syndrome | - | - |
Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
ABBV-383 (Etentamig) | Phase 2 | Immunoglobulin Light Chain (AL) Amyloidosis | - | - |
Pneumococcal 13-valent conjugate vaccine (PCV-13) | Phase 2 | Rheumatoid Arthritis | - | - |
Atrasentan | Phase 2 | Nephropathy | - | - |
Fluorouracil infusion | Phase 2 | Untreated Metastatic Colorectal Cancer | - | - |
ABBV-295 | Phase 2 | Obesity | - | - |
relapsed/refractory multiple myeloma
2 drugs in this indication
menstrual migraine
2 drugs in this indication
immunology
1 drug in this indication
psoriasis
1 drug in this indication
acute and chronic hepatitis C virus (HCV)
1 drug in this indication
multiple myeloma
1 drug in this indication
HIV/SIV reservoir reduction
1 drug in this indication
anti-wrinkle therapy
1 drug in this indication
frontline non-small cell lung cancer (NSCLC)
1 drug in this indication
Dry Eye Disease
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
relapsed/refractory multiple myeloma (RRMM)
1 drug in this indication
Hepatitis C (acute infection)
1 drug in this indication
Migraine
1 drug in this indication
Open-Angle Glaucoma
1 drug in this indication
oncology
1 drug in this indication
menstrual migraine prevention
1 drug in this indication
Colorectal Cancer (CRC) and Non-Small Cell Lung Cancer (NSCLC)
1 drug in this indication
non-segmental vitiligo
1 drug in this indication
Parkinson's disease
1 drug in this indication
Moderately to Severely Active Crohn's Disease
1 drug in this indication
Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis)
1 drug in this indication
hidradenitis suppurativa (skin disease; abscess burden)
1 drug in this indication
debilitating/painful skin disease (specific condition not named in excerpt)
1 drug in this indication
chronic skin condition
1 drug in this indication
Moderately to severely active Crohn's disease in adults
1 drug in this indication
hidradenitis suppurativa
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in AbbVie Inc.'s drug pipeline?→
CatalystAlert tracks 235 drug candidates in AbbVie Inc.'s (ABBV) pipeline across Phase 3, Phase 2. Its lead program is Venetoclax (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AbbVie Inc.'s next FDA catalyst?→
AbbVie Inc.'s (ABBV) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABBV biotech catalysts?→
Add ABBV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbbVie Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
